Producing therapeutic antibodies is expensive and difficult, but drug-makers have unprecedented flexibility in plant design through a new modular biologics manufacturing platform that streamlines the process.
This article, published in nature research, delves into how utilizing a more flexible and adaptable biologics platform can greatly reduce the time and cost of producing therapeutic molecules.
Experience J.POD manufacturing here